Salvatore Intagliata

Brescia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.

Journal: Cancer immunology, immunotherapy : CII

Published: July 06, 2021

High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases.

High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases.

Journal: Frontiers in oncology

Published: August 20, 2020

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

Journal: The Lancet. Oncology

Published: April 23, 2020

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.

Journal: Expert opinion on biological therapy

Published: February 04, 2020

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.

Journal: Advances in therapy

Published: December 12, 2019

Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice.

Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice.

Journal: Annals of translational medicine

Published: October 30, 2018

Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.

Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 25, 2018

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Journal: Scientific reports

Published: April 16, 2016

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Journal: Scientific reports

Published: July 13, 2015

Role of c-mesenchymal-epithelial transition pathway in gastric cancer.

Role of c-mesenchymal-epithelial transition pathway in gastric cancer.

Journal: Expert opinion on pharmacotherapy

Published: April 18, 2015

Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens.

Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens.

Journal: Expert opinion on therapeutic targets

Published: March 01, 2013

Premetastatic niche: ready for new therapeutic interventions?

Premetastatic niche: ready for new therapeutic interventions?

Journal: Expert opinion on therapeutic targets

Published: March 27, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026